InControl Medical
- Industry
- Medical Devices & Equipment
- Founded Year
- 2010
- Headquarters
- 3225 Gateway Road, Suite 250, Brookfield, WI 53045, USA
- Employee Count
- 21
Key People
- Herschel Peddicord - Founder and CEO
- Barbara Long - Chief Financial Officer
- Mitch Maritato - Chief Operating Officer
- Ann Koveck - Chief Clinical Officer
- Connie Harrell - Board Member
Assessment
- Team
-
Aspect: 1 successful MedTech entrepreneur
Summary: Led by experienced MedTech entrepreneur.
Founder and CEO Herschel Peddicord has over 30 years of experience in sales, marketing, and startup operations in the medical industry, including founding HomMed, LLC, which became the world's largest telemedicine company.
- Clinical Need
-
Aspect: Very Strong
Summary: Addresses significant unmet need in incontinence treatment.
InControl Medical's products, such as Attain and Apex, provide non-invasive solutions for urinary and fecal incontinence, conditions affecting a large population with limited effective treatment options.
- Competition
-
Aspect: Somewhat crowded
Summary: Competes in a moderately competitive market.
The incontinence treatment market includes various players offering both invasive and non-invasive solutions, making it moderately competitive.
- Technical Challenge
-
Aspect: Predictable
Summary: Technology is well-established and reliable.
The company's devices utilize established electrical muscle stimulation technology, reducing technical risks associated with product development.
- Patent
-
Aspect: Very Strong
Summary: Robust patent portfolio.
InControl Medical holds over 50 patents, providing strong intellectual property protection for its products.
- Financing
-
Aspect: Medium
Summary: Moderate funding history.
The company has raised approximately $3.9 million over two funding rounds, which may limit rapid expansion capabilities.
- Regulatory
-
Aspect: 510k/PMA
Summary: Products are FDA-cleared.
Devices like Attain and Apex have received FDA clearance, facilitating market entry and building consumer trust.
Opportunity Rollup
- Odds of Success
- 4.05
- Peak Market Share
- 5.45
- Segment CAGR
- 5.9%
- Market Segment
- Nephrology and Urology Devices
- Market Sub Segment
- Incontinence Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.82 |
| 3 | 1.91 |
| 4 | 3.82 |
| 5 | 5.45 |
Key Takeaway
InControl Medical, led by experienced leadership and holding a strong patent portfolio, addresses a significant clinical need with FDA-cleared, non-invasive incontinence treatment devices. While facing moderate competition and financing constraints, the company is well-positioned to capitalize on favorable industry trends.